Delta-sleep-inducing peptide is a neuropeptide that affects a number of endocrine and physiological processes within the central nervous system. DSIP is of primary interest for its abilities to reduce oxidative stress, normalize myocardial contractility.
$65 USD
Out of stock
Not for human or veterinary use. Made in USA
This product is intended as a research chemical only. Not for human use. Peptides will arrive in a lyophilized (powder) form for maximum stability.
Delta sleep-inducing peptide (DSIP) is a short peptide of natural origin. It gains its name from its ability to cause sleep in rabbits and from the fact that it was first isolated in 1977 from the brains of rats during slow-wave sleep. The peptide, however, has a number of physiologic and endocrine roles that are slowly being uncovered as it gains interest among researchers.
Right now, it is known that DSIP can alter corticotropin levels, inhibit somatostatin secretion, limit stress, normalize blood pressure, alter sleep patterns, and alter pain perception. It may also have future applications in cancer treatment, depression, and the prevention of free radical damage.
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular Formula: C₃₅H₄₈N₁₀O₁₅
Molecular Weight: 848.824 g/mol
PubChem CID: 68816
CAS Number: 62568-57-4
Synonyms: Emideltide, DSIP nonapeptide, Deltaran
DSIP is a naturally occurring peptide originally isolated from the brains of sleeping rabbits in 1977. Although its name suggests a primary role in inducing sleep, ongoing research reveals a much broader physiological impact.
DSIP’s connection to sleep remains complex. It has been shown to influence slow-wave sleep and normalize dysfunctional sleep patterns, especially in cases of chronic insomnia. While some EEG studies show limited direct sedation effects, subjective measures such as improved sleep efficiency and reduced sleep latency suggest it supports natural sleep processes.
DSIP has demonstrated the ability to reduce pain perception and improve mood in clinical trials. It also appears to lessen withdrawal symptoms in patients with opioid dependence. In rodent studies, DSIP exerts pain-relieving effects via central opioid receptors—without the addictive properties associated with traditional opioids.
DSIP supports oxidative phosphorylation even under stress-induced hypoxia, helping maintain mitochondrial efficiency. This property reduces toxic metabolic byproducts and free radical formation, suggesting strong antioxidant and anti-aging potential.
DSIP appears to stabilize monoamine oxidase A (MAO-A) activity and serotonin levels in hypoxic environments. Depressed individuals often show decreased DSIP levels in cerebrospinal fluid, indicating a potential link to mood regulation and the hypothalamic-pituitary-adrenal (HPA) axis.
Studies on DSIP’s use in alcohol and opiate detoxification show high efficacy, with many patients achieving complete symptom relief. DSIP may offer a safer, non-addictive alternative to conventional withdrawal treatments.
Long-term administration of DSIP in mice showed a 2.6x reduction in tumor incidence and a significant decrease in chromosomal damage. In chemotherapy settings, DSIP protects the central nervous system and enhances brain blood flow, reducing cognitive side effects.
DSIP may inhibit somatostatin—a protein that suppresses muscle growth—thus promoting hypertrophy and hyperplasia. It has also been observed to influence blood pressure, thermogenesis, heart rate, and immune responses. This supports the theory that DSIP has broader endocrine or hypothalamic functions beyond sleep.
DSIP has excellent subcutaneous bioavailability in mice and minimal side effects. However, its dosage and effects do not scale linearly to humans. DSIP is for research purposes only and not approved for human consumption.
Shlomo Yehuda, Ph.D. is a prolific researcher with hundreds of publications in neuroscience, thermoregulation, pharmacology, and complex mechanisms of action. His work has explored the effects of DSIP and DSIP-P in various models, including mice exposed to continuous light, DSIP’s role in sleep onset, its unique thermoregulatory behavior at different doses, and its impact on pain thresholds in light/dark cycles in rats.
Dr. Yehuda is cited as a leading figure in DSIP research. His mention here is strictly to acknowledge his contributions to the scientific community. There is no endorsement, affiliation, or association—implied or otherwise—between Dr. Yehuda and any commercial product or brand.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Shlomo Yehuda, Ph.D. is a prolific researcher with hundreds of publications in neuroscience, thermoregulation, pharmacology, and complex mechanisms of action. His work has explored the effects of DSIP and DSIP-P in various models, including mice exposed to continuous light, DSIP’s role in sleep onset, its unique thermoregulatory behavior at different doses, and its impact on pain thresholds in light/dark cycles in rats.
Dr. Yehuda is cited as a leading figure in DSIP research. His mention here is strictly to acknowledge his contributions to the scientific community. There is no endorsement, affiliation, or association—implied or otherwise—between Dr. Yehuda and any commercial product or brand.
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below:
Peptide Storage Information
This product is intended as a research chemical only. Not for human use. Peptides will arrive in a lyophilized (powder) form for maximum stability.
Delta sleep-inducing peptide (DSIP) is a short peptide of natural origin. It gains its name from its ability to cause sleep in rabbits and from the fact that it was first isolated in 1977 from the brains of rats during slow-wave sleep. The peptide, however, has a number of physiologic and endocrine roles that are slowly being uncovered as it gains interest among researchers.
Right now, it is known that DSIP can alter corticotropin levels, inhibit somatostatin secretion, limit stress, normalize blood pressure, alter sleep patterns, and alter pain perception. It may also have future applications in cancer treatment, depression, and the prevention of free radical damage.
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular Formula: C₃₅H₄₈N₁₀O₁₅
Molecular Weight: 848.824 g/mol
PubChem CID: 68816
CAS Number: 62568-57-4
Synonyms: Emideltide, DSIP nonapeptide, Deltaran
DSIP is a naturally occurring peptide originally isolated from the brains of sleeping rabbits in 1977. Although its name suggests a primary role in inducing sleep, ongoing research reveals a much broader physiological impact.
DSIP’s connection to sleep remains complex. It has been shown to influence slow-wave sleep and normalize dysfunctional sleep patterns, especially in cases of chronic insomnia. While some EEG studies show limited direct sedation effects, subjective measures such as improved sleep efficiency and reduced sleep latency suggest it supports natural sleep processes.
DSIP has demonstrated the ability to reduce pain perception and improve mood in clinical trials. It also appears to lessen withdrawal symptoms in patients with opioid dependence. In rodent studies, DSIP exerts pain-relieving effects via central opioid receptors—without the addictive properties associated with traditional opioids.
DSIP supports oxidative phosphorylation even under stress-induced hypoxia, helping maintain mitochondrial efficiency. This property reduces toxic metabolic byproducts and free radical formation, suggesting strong antioxidant and anti-aging potential.
DSIP appears to stabilize monoamine oxidase A (MAO-A) activity and serotonin levels in hypoxic environments. Depressed individuals often show decreased DSIP levels in cerebrospinal fluid, indicating a potential link to mood regulation and the hypothalamic-pituitary-adrenal (HPA) axis.
Studies on DSIP’s use in alcohol and opiate detoxification show high efficacy, with many patients achieving complete symptom relief. DSIP may offer a safer, non-addictive alternative to conventional withdrawal treatments.
Long-term administration of DSIP in mice showed a 2.6x reduction in tumor incidence and a significant decrease in chromosomal damage. In chemotherapy settings, DSIP protects the central nervous system and enhances brain blood flow, reducing cognitive side effects.
DSIP may inhibit somatostatin—a protein that suppresses muscle growth—thus promoting hypertrophy and hyperplasia. It has also been observed to influence blood pressure, thermogenesis, heart rate, and immune responses. This supports the theory that DSIP has broader endocrine or hypothalamic functions beyond sleep.
DSIP has excellent subcutaneous bioavailability in mice and minimal side effects. However, its dosage and effects do not scale linearly to humans. DSIP is for research purposes only and not approved for human consumption.
Shlomo Yehuda, Ph.D. is a prolific researcher with hundreds of publications in neuroscience, thermoregulation, pharmacology, and complex mechanisms of action. His work has explored the effects of DSIP and DSIP-P in various models, including mice exposed to continuous light, DSIP’s role in sleep onset, its unique thermoregulatory behavior at different doses, and its impact on pain thresholds in light/dark cycles in rats.
Dr. Yehuda is cited as a leading figure in DSIP research. His mention here is strictly to acknowledge his contributions to the scientific community. There is no endorsement, affiliation, or association—implied or otherwise—between Dr. Yehuda and any commercial product or brand.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Shlomo Yehuda, Ph.D. is a prolific researcher with hundreds of publications in neuroscience, thermoregulation, pharmacology, and complex mechanisms of action. His work has explored the effects of DSIP and DSIP-P in various models, including mice exposed to continuous light, DSIP’s role in sleep onset, its unique thermoregulatory behavior at different doses, and its impact on pain thresholds in light/dark cycles in rats.
Dr. Yehuda is cited as a leading figure in DSIP research. His mention here is strictly to acknowledge his contributions to the scientific community. There is no endorsement, affiliation, or association—implied or otherwise—between Dr. Yehuda and any commercial product or brand.
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below:
Peptide Storage Information
From $47 USD - $55 USD
From $306 USD - $360 USD
From $43 USD - $50 USD
From $94 USD - $110 USD
From $68 USD - $80 USD
From $43 USD - $50 USD
Receive all the latest information on events, sales, & offers.
Mon - Fri 9AM - 4PM PST
Mon - Fri (Excluding holidays)
Orders placed and paid after 12PM PST are shipped the following business day
© 2025
Ai-Peptides.com. All Rights Reserved.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Ai-Peptides is a chemical supplier. Ai-Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. AiPeptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
